ASH 2019 | Flotetuzumab for primary refractory and early relapsed AML

John DiPersio

John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, presents additional scientific data supporting the investigation of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in salvage therapy for primary refractory and early relapsed acute myeloid leukemia patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter